BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 35233862)

  • 1. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma.
    Chawla S; Bukhari S; Afridi OM; Wang S; Yadav SK; Akbari H; Verma G; Nath K; Haris M; Bagley S; Davatzikos C; Loevner LA; Mohan S
    NMR Biomed; 2022 Jul; 35(7):e4719. PubMed ID: 35233862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas.
    de Godoy LL; Mohan S; Wang S; Nasrallah MP; Sakai Y; O'Rourke DM; Bagley S; Desai A; Loevner LA; Poptani H; Chawla S
    J Transl Med; 2023 Apr; 21(1):287. PubMed ID: 37118754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma.
    Verma G; Chawla S; Mohan S; Wang S; Nasrallah M; Sheriff S; Desai A; Brem S; O'Rourke DM; Wolf RL; Maudsley AA; Poptani H
    NMR Biomed; 2019 Feb; 32(2):e4042. PubMed ID: 30556932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
    Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudoprogression in Glioblastoma: Role of Metabolic and Functional MRI-Systematic Review.
    Sidibe I; Tensaouti F; Roques M; Cohen-Jonathan-Moyal E; Laprie A
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.
    Rowe LS; Butman JA; Mackey M; Shih JH; Cooley-Zgela T; Ning H; Gilbert MR; Smart DK; Camphausen K; Krauze AV
    J Neurooncol; 2018 Aug; 139(1):145-152. PubMed ID: 29767308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudoprogression in GBM versus true progression in patients with glioblastoma: A multiapproach analysis.
    Sidibe I; Tensaouti F; Gilhodes J; Cabarrou B; Filleron T; Desmoulin F; Ken S; Noël G; Truc G; Sunyach MP; Charissoux M; Magné N; Lotterie JA; Roques M; Péran P; Cohen-Jonathan Moyal E; Laprie A
    Radiother Oncol; 2023 Apr; 181():109486. PubMed ID: 36706959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients.
    Yoo RE; Choi SH
    Magn Reson Med Sci; 2016; 15(2):165-77. PubMed ID: 26726012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.
    Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M
    Front Immunol; 2021; 12():790674. PubMed ID: 34899760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
    Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
    AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T
    Sun YZ; Yan LF; Han Y; Nan HY; Xiao G; Tian Q; Pu WH; Li ZY; Wei XC; Wang W; Cui GB
    BMC Med Imaging; 2021 Feb; 21(1):17. PubMed ID: 33535988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma.
    Akbari H; Rathore S; Bakas S; Nasrallah MP; Shukla G; Mamourian E; Rozycki M; Bagley SJ; Rudie JD; Flanders AE; Dicker AP; Desai AS; O'Rourke DM; Brem S; Lustig R; Mohan S; Wolf RL; Bilello M; Martinez-Lage M; Davatzikos C
    Cancer; 2020 Jun; 126(11):2625-2636. PubMed ID: 32129893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
    Shiroishi MS; Boxerman JL; Pope WB
    Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review.
    Bonm AV; Ritterbusch R; Throckmorton P; Graber JJ
    J Neuroimaging; 2020 Mar; 30(2):139-145. PubMed ID: 31925884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation.
    Hagiwara A; Schlossman J; Shabani S; Raymond C; Tatekawa H; Abrey LE; Garcia J; Chinot O; Saran F; Nishikawa R; Henriksson R; Mason WP; Wick W; Cloughesy TF; Ellingson BM
    J Neurooncol; 2022 Sep; 159(3):509-518. PubMed ID: 35842871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
    Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
    BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review. Part 2 - Radiological features and metric markers.
    Le Fèvre C; Constans JM; Chambrelant I; Antoni D; Bund C; Leroy-Freschini B; Schott R; Cebula H; Noël G
    Crit Rev Oncol Hematol; 2021 Mar; 159():103230. PubMed ID: 33515701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
    Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
    Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.